1166378-32-0

Basic information

• Product Name: 2,4,7-trichloro-6-bromoquinazoline
• Synonyms: 2,4,7-trichloro-6-bromoquinazoline;6-bromo-2,4,7-trichloroquinazoline
• CAS NO: 1166378-32-0
• Molecular Formula: C₈H₂BrCl₃N₂
• Molecular Weight: 312.37788
• Mol File: 1166378-32-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,4,7-trichloro-6-bromoquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,7-trichloro-6-bromoquinazoline(1166378-32-0)
• EPA Substance Registry System: 2,4,7-trichloro-6-bromoquinazoline(1166378-32-0)

Safety Data

• Hazardous Substances Data: 1166378-32-0(Hazardous Substances Data)

Usage

Heterocyclic organic compound

It contains a quinazoline ring The compound is classified as a heterocyclic organic compound because it has a quinazoline ring, which is a nitrogen-containing ring structure, in its molecule.

Quinazoline ring

A nitrogen-containing ring structure The quinazoline ring is the central structural feature of this compound, which contributes to its unique chemical properties and potential applications.

One bromine atom

Attached to the quinazoline ring The presence of a single bromine atom in the compound adds to its chemical reactivity and uniqueness.

Upstream product

• 1166378-30-8 6-bromo-7-chloroquinazoline-2,4(1H,3H)-dione 
• 765211-09-4 methyl 2-amino-5-bromo-4-chlorobenzoate 

Relevant articles and documents

COMBINATION THERAPIES FOR TREATMENT OF CANCER

Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

Synthesis and QSAR of Quinazoline Sulfonamides As Highly Potent Human Histamine H4 Receptor Inverse Agonists

Hit optimization of the class of quinazoline containing histamine H 4 receptor (H4R) ligands resulted in a sulfonamide substituted analogue with high affinity for the H4R. This moiety leads to improved physicochemical properties and is believed to probe a distinct H4R binding pocket that was previously identified using pharmacophore modeling. By introducing a variety of sulfonamide substituents, the H4R affinity was optimized. The interaction of the new ligands, in combination with a set of previously published quinazoline compounds, was described by a QSAR equation. Pharmacological studies revealed that the sulfonamide analogues have excellent H4R affinity and behave as inverse agonists at the human H4R. In vivo evaluation of the potent 2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline4-amino)-N- phenylethanesulfonamide (54) (pki = 8.31 ± 0.10) revealed it to have anti-inflammatory activity in an animal model of acute inflammation.